Isotope-Labeled Compounds

Isotope-labeled compounds are chemical substances in which some atoms in their molecules are replaced by isotope atoms. The range of stable isotope products can cover from gases to complex molecules. Isotope-labeled compounds could provide a site-specific investigation of structures, making molecules easily detectable by mass spectrometry and NMR, and maintaining the physico-chemical properties of the target molecule at the same time. MCE isotope-labeled compounds are all stable isotope-labeled compounds and are non-radioactive labeled substances. MCE isotope-labeled compounds are unique tools for identifying and understanding biological and chemical processes. Stable isotope-labeled products are now getting more and more popular among scientists. The scope of application is gradually penetrating into various scientific fields, such as life sciences, food and medicine, agriculture, environment, geology, etc. Stable isotope-labeled compounds have a wide range of applications in the Life Science areas, such as Metabolomics, Proteomics, Clinical studies, Deuterium drugs, etc.

Isotope-Labeled Compounds Inhibitors (4)

Isotope-Labeled Compounds Related Products (10876):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-N7046S

Silybin B-d₃
Silybin B-d₃ (Silibinin B-d₃) is a deuterated Silybin B (HY-N7046). Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity.

HY-134178S1

5-F-UTP-¹³C,¹⁹F,d₁
5-F-UTP-¹³C,¹⁹F,d₁ is deuterium and ¹³C-labeled 5-F-UTP (HY-134178).

HY-132402S

N-Propionyl Mesalazine-d₃
N-Propionyl Mesalazine-d₃ is the deuterium labeled N-Propionyl Mesalazine.

HY-183681S1

Mal-C6-Gly-Phe-Cpg-7-MAD-MDCPT-d₂
Mal-C6-Gly-Phe-Cpg-7-MAD-MDCPT-d₂ is the deuterium labeled Mal-C6-Gly-Phe-Cpg-7-MAD-MDCPT.

HY-114826S

Prostaglandin E2-1-glyceryl ester-d₅
Prostaglandin E2-1-glyceryl ester-d₅ (PGE2-1-glyceyl ester-d₅) is deuterium labeled Prostaglandin E2-1-glyceryl ester. Prostaglandin E2-1-glyceryl ester, a Prostaglandin Glycerol Ester, is an endocannabinoid ligand for the CB₁ receptor. Prostaglandin E2-1-glyceryl ester induces rapid, transient elevation of intracellular free Ca²⁺.

HY-B0949S

Protriptyline (N-methyl-d₃) hydrochloride
Protriptyline (N-methyl-d₃) (hydrochloride) is the deuterium labeled Protriptyline hydrochloride. Protriptyline hydrochloride is a tricyclic antidepressant (TCA), specifically a secondary amine, for the treatment of depression and ADHD. Unique among the TCAs, protriptyline tends to be energizing instead of sedating, used for narcolepsy to achieve a wakefulness-promoting effect.

HY-W742417

Tazarotenic acid-d₈
Tazarotenic acid-d₈ (AGN 190299-d₈) is the deuterium labeled Tazarotenic acid (HY-101108). Tazarotenic acid is the metabolite of Tazarotene (HY-15388).

HY-W759629

Selpercatinib-d₃
Selpercatinib-d₃ (LOXO-292-d₃) is deuterium labeled Selpercatinib. Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC₅₀ values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity.

HY-W778064

L-threo-Droxidopa-¹³C₂
L-threo-Droxidopa-¹³C₂,¹⁵N is ¹³C- and ¹⁵N-labeled L-threo-Droxidopa.

HY-P6425S

LCADMEDV-Arg(¹³C₆,¹⁵N₄) TFA
LCADMEDV-Arg(¹³C₆, ¹⁵N₄) TFA is a peptide containing ¹³C₆ and ¹⁵N₄ labeled Arg.

HY-113308AS1

Taurolithocholic Acid-d₅ sodium
Taurolithocholic Acid-d₅ (sodium) is the deuterium labeled Taurolithocholic acid sodium salt. Taurolithocholic Acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic Acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic Acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic Acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic Acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic Acid sodium salt not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.

HY-W007497S

H-β-Ala-NH2.-d₄ HCl
H-β-Ala-NH2.-d₄ HCl is the deuterium labeled H-β-Ala-NH2.HCl.

HY-17498S3

Atenolol-¹³C₆
Atenolol-¹³C₆ ((RS)-Atenolol-¹³C₆) is ¹³C labeled Atenolol. Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a K_i of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris.

HY-17464S2

Cilostazol-d₂
Cilostazol-d₂ (OPC 13013-d₂) is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM.

HY-W758734

(E)-Fenpyroximate-d₉
(E)-Fenpyroximate-d₉ is the deuterium labeled (E)-Fenpyroximate.

HY-W191560S

N1-(4-Nitrophenyl)sulfanilamide-d₄		98.0%
N1-(4-Nitrophenyl)sulfanilamide-d4 is the deuterium labeled N1-(4-Nitrophenyl)sulfanilamide.

HY-174353S

CYP51-IN-23-d₃	Inhibitor
CYP51-IN-23-d₃ is a potent and broad-spectrum CYP51 inhibitor with a MIC₈₀ of 1 μg/mL against Aspergillus fumigatum. CYP51-IN-23-d₃ can prevent fungal phase transformation and biofilm formation. CYP51-IN-23-d₃ exhibits anti-drug resistance activity and fungal activity, and shows excellent safety for cells and significant pharmacological activity in mice. CYP51-IN-23-d₃ can be used for the study of invasive fungal infections (IFIs).

HY-17464S3

Cilostazol-d₆
Cilostazol-d₆ (OPC 13013-d₆) is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM.

HY-W703549

Aderbasib-d₃
Aderbasib-d₃ (INCB007839-d₃) is deuterium labeled Aderbasib. Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2⁺?breast cancer, gliomas, et al.

HY-B1138S

Fenbufen-d₉
Fenbufen-d₉ (CL-82204-d₉) is the deuterium labeled Fenbufen. Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC₅₀s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor.

Name
Email *

	Sorry, but the email address you supplied was invalid.